Search clinical trials for: Non-small call lung cancer

Total 139075 results

GlaxoSmithKline

Not yet recruiting

Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Patient-derived Organoids and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)

Lung Cancer, Non-Small Cell

United Kingdom
Amgen

Recruiting

AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol)

Non-small Cell Lung Cancer | Thoracic Tumors

United States
GlaxoSmithKline

Recruiting

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

Neoplasms

United States, Spain, Korea, Republic of
Pfizer

Recruiting

A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors

Melanoma | Neoplasms | Renal Cell Carcinoma | Non-small-cell Lung Cancer | Squamous Cell Carcinoma of the Head and Neck | Urothelial Carcinoma | Colorectal Carcinoma | Ovarian Carcinoma

United States, Japan, Puerto Rico
Amgen

Recruiting

A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

Advanced Solid Tumors

Australia, United States, Japan, Korea, Republic of
Incyte Corporation

Recruiting

A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive

Advanced Solid Tumor

Brazil, Georgia, Greece, Turkey, Mexico, Romania, South Africa, Hungary, New Zealand, China
Totus Medicines

Recruiting

A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With Select Solid Tumors

Cervical Cancer | Gastric Cancer | Colorectal Cancer | Ovarian Cancer | Squamous Cell Carcinoma of Head and Neck | Endometrial Cancer | Non-small Cell Lung Cancer | Urothelial Carcinoma | HER2-negative Breast Cancer

United States
ProfoundBio US Co.

Recruiting

PRO1184 for Advanced Solid Tumors (PRO1184-001)

Ovarian Cancer | Fallopian Tube Cancer | Mesothelioma | Triple Negative Breast Cancer | Endometrial Cancer | Non-small Cell Lung Cancer | Primary Peritoneal Carcinoma | Breast Adenocarcinoma | High Grade Epithelial Ovarian Cancer | Hormone Receptor-positive/Her2 Negative Breast Cancer

United States, China
GlaxoSmithKline
iTeos Therapeutics

Recruiting

A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

Lung Cancer, Non-Small Cell

Finland, Italy, Netherlands, Spain, United States, Argentina, Belgium, Brazil, Germany, Greece, Hungary, Korea, Republic of, United Kingdom, Poland, France, Thailand, Japan, South Africa, Turkey, United Arab Emirates, Mexico, Port...
GlaxoSmithKline

Recruiting

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

Neoplasms

United States, Australia, Spain, Canada, France, Korea, Republic of, United Kingdom, Japan, China
Seagen Inc.

Recruiting

A Study of SGN-PDL1V in Advanced Solid Tumors

Melanoma | Carcinoma, Non-Small-Cell Lung | Gastric Cancer | Ovarian Neoplasms | Squamous Cell Carcinoma of the Head and Neck | Triple Negative Breast Neoplasms | Esophageal Squamous Cell Carcinoma

United States, Spain, Italy, Canada, United Kingdom, France, Belgium, Germany, Netherlands
Seagen Inc.

Recruiting

A Study of SGN-B7H4V in Advanced Solid Tumors

Carcinoma, Non-Small-Cell Lung | Adenoid Cystic Carcinoma | Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms | Endometrial Neoplasms | Cholangiocarcinoma | Triple Negative Breast Neoplasms | Gallbladder Carcinoma | HER2 Negative Breast Neoplasms | Hormone Receptor Positive Breast Neoplasms

United States, Spain, Canada, United Kingdom, Germany, Italy
Pfizer

Recruiting

Crizotinib Continuation Clinical Study

NSCLC | IMT | ALCL

China, Taiwan, Japan, Russian Federation, Italy
Amgen

Recruiting

AMG 193, Methylthioadenosine (MTA) Cooperative Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, Alone and in Combination With Docetaxel in Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors (MTAP)

Advanced MTAP-null Solid Tumors

United States, Canada, Taiwan, Switzerland, United Kingdom, Korea, Republic of, Germany, Austria, France, Belgium, Australia, Hong Kong, Japan
Pierre Fabre Medicament

Recruiting

A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

Melanoma | Non-small Cell Lung Cancer | Solid Tumor, Adult

United States, Australia, France, Spain, Taiwan, Korea, Republic of, China, Netherlands
Pfizer

Not yet recruiting

A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer

Cervical Cancer | Metastatic Colorectal Cancer | Fallopian Tube Cancer | Metastatic Breast Cancer | Epithelial Ovarian Cancer | Non-small Cell Lung Cancer | Primary Peritoneal Cancer | Metastatic Kidney Cancer
Amgen

Recruiting

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

Chemotherapy-induced Thrombocytopenia

United States, Spain, Turkey, Argentina, Greece, Austria, Brazil, Bulgaria, Chile, Colombia, Mexico, Peru, Poland, Portugal, Romania, Russian Federation, Ukraine, Hungary
Pfizer

Recruiting

Safety and Efficacy of Lorbrena

Non-small Cell Lung Cancer

Japan
Inhibrx, Inc.

Recruiting

Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer (PDL1x41BB)

Melanoma | Renal Cell Carcinoma | Nasopharyngeal Carcinoma | Gastric Adenocarcinoma | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Esophageal Adenocarcinoma | Metastatic Solid Tumors | Oropharyngeal Carcinoma

United States
GlaxoSmithKline
iTeos Belgium SA

Recruiting

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)

Neoplasms

United States, Italy, Spain, France, Germany, Canada, Korea, Republic of, Netherlands, Poland, Romania, Russian Federation, Sweden
Pfizer

Recruiting

Safety and Efficacy of Xalkori ROS1

Non-small Cell Lung Cancer

Japan
Tesaro, Inc.

Recruiting

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

Neoplasms

United States, Spain, Korea, Republic of
Tesaro, Inc.

Recruiting

Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors (GARNET)

Neoplasms

United States, Italy, Spain, Korea, Republic of, Canada, France, United Kingdom, Poland, Mexico, Czechia, Denmark, Argentina, Brazil
Pfizer

Active, not recruiting

Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15 (PROACC-1)

Fatigue | Colorectal Cancer | Pancreatic Cancer | Cachexia | Non-small Cell Lung Cancer | Loss of Appetite

China, United States, Canada, Hungary, Australia, Slovakia, Japan, Taiwan, Bulgaria, Poland, Spain, Czechia
Pfizer

Completed

Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.

Ovarian Cancer | Non-Small Cell Lung Cancer | Squamous Cell Carcinoma of the Head and Neck

United States, Spain
Pfizer

Active, not recruiting

Study of PF-07265807 in Participants With Metastatic Solid Tumors.

Neoplasm Metastasis

United States, Spain, Canada, Korea, Republic of, Australia, Japan, Italy, China
AbbVie

Active, not recruiting

Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

United States, Australia, Belgium, Bulgaria, Canada, China, Czechia, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Netherlands, Poland, Puerto Rico, Romania, Russian Federation, Spain, Switzerland and more
Pfizer

Withdrawn

Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.

Breast Cancer | Ovarian Cancer | Non-small Cell Lung Cancer (NSCLC) | Solid Tumors | Liposarcoma | Endometrial
Famewave Ltd.

Terminated

Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)

Melanoma | Gastric Cancer | Colorectal Cancer | Ovarian Cancer | Bladder Cancer | Non-small Cell Lung Carcinoma (NSCLC)

United States, Israel
Optimum Therapeutics, LLC

Terminated

Evaluation of Non-cytotoxic Suramin as a Chemosensitizer in Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

United States
Ass. Prof. Jan Nyman
Karolinska Institutet; Göteborg University

Unknown

Stereotactic Precision And Conventional Radiotherapy Evaluation (SPACE)

Non-small Cell Lung Cancer
Georgetown University
Regeneron Pharmaceuticals

Not yet recruiting

Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advance Non-Small Cell Lung Cancer (NEO-SURG)

Non-small Cell Lung Cancer Stage III

United States
Pfizer

Recruiting

A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination (LTbR)

Melanoma | Colorectal Cancer | Non-Small Cell Lung Cancer | Urothelial Cancer | Advanced or Metastatic Solid Tumors

United States, Puerto Rico
Bristol-Myers Squibb

Not yet recruiting

Patient and Physician Preference Study in Resectable, Non-small Cell Lung Cancer Treatments

Non-small Cell Lung Cancer (NSCLC)

United Kingdom
Pfizer

Not yet recruiting

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

Carcinoma, Non-Small-Cell Lung | Colorectal Neoplasms | Carcinoma, Pancreatic Ductal
AstraZeneca

Not yet recruiting

Volrustomig Priming Regimens Exploratory Phase II Platform Study (eVOLVE-01)

Non-small Cell Lung Cancer
KaliVir Immunotherapeutics

Not yet recruiting

A Study of VET3-TGI in Patients With Solid Tumors (STEALTH-001)

Kidney Cancer | Renal Cell Carcinoma | Cervical Cancer | Mesothelioma | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Solid Tumor, Adult | Microsatellite Stable Colorectal Cancer | Melanoma Stage IV | Merkel Cell Carcinoma of Skin
Daping Hospital and the Research Institute of Surgery...

Not yet recruiting

Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC

Non Small Cell Lung Cancer | Non Small Cell Lung Cancer Stage IIIB | EGFR Gene Mutation | Non-small Cell Lung Cancer Stage IV
Amgen

Not yet recruiting

Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab) (Eucalyptus)

Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)
National University Hospital, Singapore

Not yet recruiting

A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers (VALUE-CHECK)

Carcinoma, Hepatocellular | Gastric Adenocarcinoma | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Oesophageal Cancer | GastroEsophageal Cancer

Singapore
Merck Sharp & Dohme LLC

Not yet recruiting

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

NSCLC | Non-small Cell Lung Cancer
AstraZeneca
Daiichi Sankyo

Not yet recruiting

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung15)

Metastatic Non-small Cell Lung Cancer
Henan Cancer Hospital
Kingbio Medical (Beijing) Co., Ltd.

Recruiting

Patient-derived Organoid Drug Sensitivity Guided Treatment for Drug-resistant Recurrent Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Qilu Pharmaceutical Co., Ltd.

Recruiting

A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors

Colorectal Cancer | Pancreatic Cancer | Solid Tumor | Non-small Cell Lung Cancer

China
Changzhou No.2 People's Hospital

Not yet recruiting

FMT+Immunotherapy+Chemotherapy as First-line Treatment for Driver-gene Negative Advanced NSCLC

Non-small Cell Lung Cancer
West China Hospital

Not yet recruiting

Neoadjuvant Chemoimmunotherapy in Stage IIIA- N2IIIB Non-small Cell Lung Cancer

Non-small Cell Lung Cancer Stage IIIB | Non-small Cell Lung Cancer Stage ⅢA
Peking Union Medical College Hospital

Not yet recruiting

ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI

Non-small Cell Lung Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
AstraZeneca

Not yet recruiting

Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC (FOREFRONT)

Neoplasms | Respiratory Tract Diseases | Lung Diseases | Neoplasms by Site | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms

China

Search clinical trials for: Non-small call lung cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belgium

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations